Precision BioSciences (DTIL) has a market capitalization of approximately $94M, trading at $7.30 on the NASDAQ. Market cap moves with the live share price.
Precision BioSciences's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Precision BioSciences runs a net profit margin of -96.7%, a gross margin of 100.0%, and an operating margin of -86.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Precision BioSciences reported revenue of
Precision BioSciences does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Precision BioSciences carries a debt-to-equity ratio of 0.37x and a current ratio of 14.02x, with a market beta of 1.25. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Precision BioSciences (DTIL) the key facts are: market cap $94M, revenue
Get Precision BioSciences's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.